Tom 16, Nr 2 (2020)
Artykuły przeglądowe
Opublikowany online: 2020-06-30
Pobierz cytowanie

Leki przeciwpadaczkowe i bezpieczeństwo ich stosowania w okresie ciąży i karmienia piersią — przegląd aktualnych danych

Miłosz Jan Gołyszny, Oliwia Korzonek, Magdalena Durańska
DOI: 10.5603/PPN.2020.0015
·
Pol. Przegl. Neurol 2020;16(2):88-104.

dostęp płatny

Tom 16, Nr 2 (2020)
Artykuły przeglądowe
Opublikowany online: 2020-06-30

Streszczenie

Leczenie padaczki (epilepsji) u kobiety w ciąży to zadanie dla neurologa oraz ginekologa-położnika. Stosowanie leków przeciwpadaczkowych jest konieczne, mimo że może prowadzić do aberracji w przebiegu ciąży, ponieważ nieleczona padaczka stanowi zagrożenie dla matki i rozwijającego się płodu. FDA (Food and Drug Administration) oraz ADEC (Australian Drug Evaluation Comittee) wprowadziły klasyfikacje mające na celu określenie ryzyka uszkodzenia zarodka/płodu w wyniku stosowania leków. Najstarsze leki przeciwpadaczkowe (leki I-generacji) są bardzo skuteczne, jednakże wiadomo, ze ich stosowanie niesie ze sobą największe ryzyko indukcji anomalii u płodu. Dodatkowo, podobnie jak w przypadku stosowania benzodiazepin, istnieje ryzyko rozwoju u noworodków syndromu odstawienia. Leki II-generacji nie zostały dotychczas dokładnie przebadane pod kątem działania embriotoksycznego i teratogennego. Jednakże dostępne dane sugerują, że są to leki bezpieczniejsze. Benzodiazepiny stanowią odrębną grupę leków o potencjale przeciwdrgawkowym. Podawanie tych leków w okresie ciąży musi być wysoce uzasadnione, biorąc pod uwagę bilans korzyści i istotnych zagrożeń wynikających z ich stosowania.

Streszczenie

Leczenie padaczki (epilepsji) u kobiety w ciąży to zadanie dla neurologa oraz ginekologa-położnika. Stosowanie leków przeciwpadaczkowych jest konieczne, mimo że może prowadzić do aberracji w przebiegu ciąży, ponieważ nieleczona padaczka stanowi zagrożenie dla matki i rozwijającego się płodu. FDA (Food and Drug Administration) oraz ADEC (Australian Drug Evaluation Comittee) wprowadziły klasyfikacje mające na celu określenie ryzyka uszkodzenia zarodka/płodu w wyniku stosowania leków. Najstarsze leki przeciwpadaczkowe (leki I-generacji) są bardzo skuteczne, jednakże wiadomo, ze ich stosowanie niesie ze sobą największe ryzyko indukcji anomalii u płodu. Dodatkowo, podobnie jak w przypadku stosowania benzodiazepin, istnieje ryzyko rozwoju u noworodków syndromu odstawienia. Leki II-generacji nie zostały dotychczas dokładnie przebadane pod kątem działania embriotoksycznego i teratogennego. Jednakże dostępne dane sugerują, że są to leki bezpieczniejsze. Benzodiazepiny stanowią odrębną grupę leków o potencjale przeciwdrgawkowym. Podawanie tych leków w okresie ciąży musi być wysoce uzasadnione, biorąc pod uwagę bilans korzyści i istotnych zagrożeń wynikających z ich stosowania.

Pobierz cytowanie

Słowa kluczowe

leki przeciwpadaczkowe, ciąża, okres laktacji

Informacje o artykule
Tytuł

Leki przeciwpadaczkowe i bezpieczeństwo ich stosowania w okresie ciąży i karmienia piersią — przegląd aktualnych danych

Czasopismo

Polski Przegląd Neurologiczny

Numer

Tom 16, Nr 2 (2020)

Strony

88-104

Data publikacji on-line

2020-06-30

DOI

10.5603/PPN.2020.0015

Rekord bibliograficzny

Pol. Przegl. Neurol 2020;16(2):88-104.

Słowa kluczowe

leki przeciwpadaczkowe
ciąża
okres laktacji

Autorzy

Miłosz Jan Gołyszny
Oliwia Korzonek
Magdalena Durańska

Referencje (126)
  1. Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG. 2009; 116(6): 758–767.
  2. Alsmadi MM, Idkaidek N. Optimization of drugs pharmacotherapy during pregnancy using physiologically based pharmacokinetic models — an update. Curr Drug Metab. 2018; 19(12): 972–978.
  3. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs. 2007; 67(18): 2727–2746.
  4. Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019; 21(6): 497–517.
  5. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus. Report of the ILAE Task Force on classification of status epilepticus. Epilepsia. 2015; 56(10): 1515–1523.
  6. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP Epilepsy Pregnancy Registry. Neurology. 2005; 66(3): 354–360.
  7. Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet. 2011; 378(9808): 2028–2038.
  8. Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia. 2014; 55(7): e72–e74.
  9. Bargieł A, Bokiniec R, Kornacka MK. Risk factors for preterm encephalopathy. Ginekol Pol. 2009; 80(8): 620–623.
  10. Wijdicks EFM. Determining brain death in adults. Neurology. 1995; 45(5): 1003–1011.
  11. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012; 11(9): 803–813.
  12. Meador K, Reynolds M, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008; 81(1): 1–13.
  13. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10(7): 609–617.
  14. Pandey MK, Mittra P, Maheshwari P. Oxidative stress in epilepsy with comorbid psychiatric illness. Natl J Physiol Pharm Pharmacol. 2013; 3(1): 92.
  15. Holmes GL, Ben-Ari Y. The neurobiology and consequences of epilepsy in the developing brain. Pediatr Res. 2001; 49(3): 320–325.
  16. Werler MM, Ahrens KA, Bosco JLF, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011; 21(11): 842–850.
  17. Tomson T, Battino D, Bonizzoni E, et al. EURAP: an International Registry of Antiepileptic Drugs and Pregnancy. Epilepsia. 2004; 45(11): 1463–1464.
  18. Bromley RL, Baker GA. Fetal antiepileptic drug exposure and cognitive outcomes. Seizure. 2017; 44: 225–231.
  19. Shorvon SD. The first 100 years of the ILAE (1909–2009): its landmarks, achievements, and challenges. Epilepsia Open. 2019; 4(2): 237–246.
  20. Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012; 53: 40–46.
  21. Yasiry Z, Shorvon S. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia. 2012; 53: 26–39.
  22. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018; 17(6): 530–538.
  23. Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: a systematic review. Epileptic Disord. 2011; 13(4): 349–365.
  24. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000; 41(11): 1436–1443.
  25. Adams J, Holmes LB, Janulewicz P. The adverse effect profile of neurobehavioral teratogens: phenobarbital. Neurotoxicol Teratol. 2004; 26(3): 507.
  26. El-Dib M, Soul J. The use of phenobarbital and other anti-seizure drugs in newborns. Semin Fetal Neonatal Med. 2017; 22(5): 321–327.
  27. Pizzo F, Dilaghi A, Romoli A, et al. Pregnancy in epileptic patients: comparison between well-established therapeutic strategies and opportunities coming from new drugs. Clinical Management Issues. 2013; 7(3): 91–98.
  28. Kazmin A, Wong RC, Sermer M, et al. Antiepileptic drugs in pregnancy and hemorrhagic disease of the newborn: an update. Can Fam Physician. 2010; 56(12): 1291–1292.
  29. Sarmento A, Soares P. Convulsões neonatais-qual a etiologia? Nascer e Crescer. 2004; 13(2): 106–112.
  30. Lander CM. Antiepileptic drugs in pregnancy and lactation. Aust Prescriber. 2008; 31(3): 70–72.
  31. Davanzo R, Bo SD, Bua J, et al. Antiepileptic drugs and breastfeeding. Ital J Pediatr. 2013; 39(1): 50.
  32. Veiby G, Bjørk M, Engelsen B, et al. Epilepsy and recommendations for breastfeeding. Seizure. 2015; 28: 57–65.
  33. Jackson L. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2004; 89(4): F300–F304.
  34. Mutschler E. Dynamics of pharmacology and toxicology drugs. ITB, Bandung 1999: 56–62.
  35. Loughnan PM, Vance JC, Gold H. Phenytoin teratogenicity in man. Lancet. 1973; 301(7794): 70–72.
  36. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr. 1975; 87(2): 285–290.
  37. Hanson JW, Smith DW. Fetal hydantoin syndrome. Lancet. 1976; 1(7961): 692.
  38. Hanson JW. Fetal hydantoin effects. Teratology. 1986; 33(3): 349–353.
  39. Hegde A, Kaur A, Sood A, et al. Fetal hydantoin syndrome. J Pediatr. 2017; 188: 304.
  40. Czeizel AE, Bod M, Halász P. Evaluation of anticonvulsant drugs during pregnancy in a population-based Hungarian study. Eur J Epidemiol. 1992; 8(1): 122–127.
  41. Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: Relationship to maternal anticonvulsant therapy. Brain Dev. 1992; 14(6): 371–380.
  42. Borgelt L, Hart F, Bainbridge J. Epilepsy during pregnancy: focus on management strategies. Int J Womens Health. 2016; 8: 505–517.
  43. Allen RW. Fetal hydantoin syndrome, neuroblastoma, and hemorrhagic disease in a neonate. JAMA. 1980; 244(13): 1464–1465.
  44. Eadie MJ, Vajda F. (eds.). Antiepileptic drugs. Pharmacology and therapeutics. Springer Science & Business Media, Basel 2012.
  45. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy — focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009; 73(2): 133–141.
  46. Harden CL, Pennell PB, Koppel BS, et al. Practice Parameter update: management issues for women with epilepsy — focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009; 73(2): 142–149.
  47. Hernández-Díaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000; 343(22): 1608–1614.
  48. Bell RD, Pak CYC, Zerwekh J, et al. Effect of phenytoin on bone and vitamin D metabolism. Ann Neurol. 1979; 5(4): 374–378.
  49. Espinosa PS, Perez DL, Abner E, et al. Association of antiepileptic drugs, vitamin D, and calcium supplementation with bone fracture occurrence in epilepsy patients. Clin Neurol Neurosurg. 2011; 113(7): 548–551.
  50. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011; 10(7): 609–617.
  51. Jentink J, Loane M, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engld J Med. 2010; 362(23): 2185–2193.
  52. Morrow J. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006; 77(2): 193–198.
  53. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006; 67(3): 407–412.
  54. Özkan H, Çetinkaya M, Köksal N, et al. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med. 2011; 24(3): 521–524.
  55. Pennell PB, Klein AM, Browning N, et al. Differential effects of antiepileptic drugs on neonatal outcomes. Epilepsy Behav. 2012; 24(4): 449–456.
  56. Almgren M, Källén B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero — influence on head circumference in newborns. Seizure. 2009; 18(10): 672–675.
  57. Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4): 383–389.
  58. Christensen J, Grønborg T, Sørensen M, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013; 309(16): 1696.
  59. Uguz F, Sharma V. Mood stabilizers during breastfeeding: a systematic review of the recent literature. Bipolar Disord. 2016; 18(4): 325–333.
  60. Vajda FJE, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs — the Australian experience. J Clin Neurosci. 2012; 19(1): 57–59.
  61. Vajda FJE, O’Brien TJ, Graham J, et al. Is carbamazepine a human teratogen? J Clin Neurosci. 2016; 23: 34–37.
  62. Akar M, Dilli D, Yilmaz Y. A case of fetal carbamazepine syndrome with right hemihypoplasia of the entire body. Genetic Couns. 2012; 23(1): 19.
  63. Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archiv Dis Child. 2011; 96(7): 643–647.
  64. Nadebaum C, Anderson VA, Vajda F, et al. Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology. 2011; 76(8): 719–726.
  65. Pennell PB. Use of antiepileptic drugs during pregnancy: evolving concepts. Neurotherapeutics. 2016; 13(4): 811–820.
  66. Sabers A, Tomson T. Managing antiepileptic drugs during pregnancy and lactation. Curr Opin Neurol. 2009; 22(2): 157–161.
  67. Dodd S, Berk M. The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium. Curr Drug Saf. 2006; 1(1): 25–33.
  68. Holmes LB. Fetal effects of anticonvulsant polytherapies. Archiv Neurol. 2011; 68(10): 1275.
  69. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012; 78(21): 1692–1699.
  70. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005; 64(6): 955–960.
  71. Vajda FJE, Graham JE, Hitchcock AA, et al. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure. 2010; 19(9): 558–561.
  72. Campbell E, Kennedy F, Irwin B, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy. J Neurol Neurosurg Psychiatry. 2013; 84(11): e2.148–e2.
  73. Dolk H, Wang H, Loane M, et al. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Neurology. 2016; 86(18): 1716–1725.
  74. Wlodarczyk BJ, Palacios AM, George TM, et al. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A. 2012; 158A(8): 2071–2090.
  75. Hunt SJ, Craig JJ, Morrow JI, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2009; 72(12): 1108–1109.
  76. Newport DJ, Pennell PB, Calamaras MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics. 2008; 122(1): e223–e231.
  77. Meischenguiser R, D'Giano C, Ferraro S. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav. 2004; 5(2): 163–167.
  78. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005; 64(11): 1874–1878.
  79. Mølgaard-Nielsen D, Hviid A. Newer-generation entiepileptic drugs and the risk of major birth defects. JAMA. 2011; 305(19).
  80. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother. 2014; 12(6): 707–717.
  81. Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin. 2005; 21(5): 693–701.
  82. Uludag S. Oxcarbazepine/topiramate multiple fetal anomalies following in utero. Reactions. 2012; 1407: 23.
  83. Veroniki AA, Rios P, Cogo E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017; 7(7): e017248.
  84. Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003; 60(4): 575–579.
  85. Hvas CL, Henriksen T, ostergaard J, et al. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. BJOG. 2000; 107(7): 896–902.
  86. Oyebode F, Rastogi A, Berrisford G, et al. Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther. 2012; 135(1): 71–77.
  87. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008; 71(4): 272–276.
  88. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011; 134(2): 396–404.
  89. Koo J, Zavras A. Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral Dis. 2013; 19(7): 712–720.
  90. Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA. 2017; 318(17): 1700.
  91. Green MW, Seeger J, Peterson C, et al. Utilization of topiramate during pregnancy and risk of birth defects. Headache. 2012; 52(7): 1070–1084.
  92. Rihtman T, Parush S, Ornoy A. Preliminary findings of the developmental effects of in utero exposure to topiramate. Reprod Toxicol. 2012; 34(3): 308–311.
  93. López-Fraile IP, Cid A, Juste A, et al. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: Clinical and outcome implications. Epilepsy Behav. 2009; 15(3): 372–375.
  94. Scheuerle AE, Holmes L, Albano J, et al. Levetiracetam Pregnancy Registry: final results and a review of the impact of registry methodology and definitions on the prevalence of major congenital malformations. Birth Defects Res. 2019; 111(13): 872–887.
  95. Montouris G, Harden, C, Alekar S, et al. UCB Antiepileptic Drug Pregnancy Registry-Keppra® data. American Epilepsy Society. 2010; abstracts: 1–257.
  96. Longo B, Forinash A, Murphy J. Drug information rounds levetiracetam use in pregnancy. Ann Pharmacother. 2009; 43(10): 1692–1695.
  97. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav. 2003; 4(4): 447–448.
  98. Bromley RL, Calderbank R, Cheyne C, et al. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016; 87(18): 1943–1953.
  99. Chaudhry SA, Jong G, Koren G. The fetal safety of levetiracetam: a systematic review. Reprod Toxicol. 2014; 46: 40–45.
  100. Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012; 94(8): 599–606.
  101. Guttuso T, Shaman M, Thornburg. LL. Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014; 181: 280–283.
  102. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav. 2003; 4(3): 310–317.
  103. Fujii H, Goel A, Bernard N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013; 80(17): 1565–1570.
  104. Rolnitsky A, Merlob P, Klinger G. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol. 2013; 48(6): 466–468.
  105. Rejdak R, Rola R, Mazurkiewicz-Bełdzińska M. Diagnosis and treatment of epilepsy in adults — recommendations of the Polish Neurological Society. Pol Przegl Neurol. 2016; 12(1): 15–27.
  106. Trinka E, Shorvon S. A decade of progress in status epilepticus 2007–2017: proceedings of the 6th London–Innsbruck Colloquium on Status Epilepticus and Acute Seizures. Epilepsia. 2018; 59: 67–69.
  107. Bresnahan R, Martin-McGill K, Williamson J, et al. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2019(10): CD004154.
  108. Perault MC, Favrelière S, Minet P, et al. [Benzodiazepines and pregnancy] [Article in French]. Therapie. 2000; 55(5): 587–595.
  109. Dolovich LR. Teratogenicity of benzodiazepines assessed. Reactions. 1998; 721: 3.
  110. Iqbal MM, Sobhan T, Aftab SR, et al. Diazepam use during pregnancy: a review of the literature. Del Med J. 2002; 74(3): 127–135.
  111. Enato E, Moretti M, Koren G. Motherisk rounds: the fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011; 33(1): 46–48.
  112. Lin AE, Peller AJ, Westgate MN, et al. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol. 2004; 70(8): 534–536.
  113. Azparren A, Garcia I. Strategies for discontinuing benzodiazepines. Drug Ther Bull Navarre. 2014; 22: 1–12.
  114. Kelly LE, Poon S, Madadi P, et al. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr. 2012; 161(3): 448–451.
  115. Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 2014; 70(11): 1361–1366.
  116. https://www medicines org uk/emc/product/4524/smpc (April 17, 2020).
  117. Czeizel AE, Erös E, Rockenbauer M, et al. Short-term oral diazepam treatment during pregnancy. Clin Drug Invest. 2003; 23(7): 451–462.
  118. Kjær D, Horvath-Puhó E, Christensen J, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf. 2007; 16(2): 181–188.
  119. Gidai J, Ács N, Bánhidy F, et al. No association found between use of very large doses of diazepam by 112 pregnant women for a suicide attempt and congenital abnormalities in their offspring. Toxicol Ind Health. 2008; 24(1-2): 29–39.
  120. https://www medicines org uk/emc/product/6022/smpc (April 17, 2020).
  121. Jarita D, Errol F, Thomas M, et al. Risk of malformation with combination of lamotrigine and low dose clonazepam for juvenile myoclonic epilepsy in pregnancy: a case report. Neurology Asia. 2010; 15(1): 79–81.
  122. Bansal R, Suri V, Chopra S, et al. Change in antiepileptic drug prescription patterns for pregnant women with epilepsy over the years: Impact on pregnancy and fetal outcomes. Ind J Pharmacol. 2019; 51(2): 93.
  123. Andrade C. Gestational exposure to benzodiazepines, 3: clobazam and major congenital malformations. J Clin Psychiatry. 2019; 80(6): 19f13151.
  124. Iqbal M, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatric Serv. 2002; 53(1): 39–49.
  125. Bais B, Molenaar NM, Bijma HH, et al. Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: A systematic review and meta-analysis. J Affect Disord. 2020; 269: 18–27.
  126. Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf. 2007; 16(11): 1203–1210.

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel. +48 58 320 94 94, faks +48 58 320 94 60, e-mail: viamedica@viamedica.pl